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Abstract
Background: Leber’s hereditary optic neuropathy (LHON) is a maternally inherited blinding disorder, which in over 90% of
cases is due to one of three primary mitochondrial DNA (mtDNA) point mutations (m.11778G.A, m.3460G.A and
m.14484T.C, respectively in MT-ND4, MT-ND1 and MT-ND6 genes). However, the spectrum of mtDNA mutations causing
the remaining 10% of cases is only partially and often poorly defined.
Methodology/Principal Findings: In order to improve such a list of pathological variants, we completely sequenced the
mitochondrial genomes of suspected LHON patients from Italy, France and Germany, lacking the three primary common
mutations. Phylogenetic and conservation analyses were performed. Sixteen mitochondrial genomes were found to harbor
at least one of the following nine rare LHON pathogenic mutations in genes MT-ND1 (m.3700G.A/p.A132T, m.3733G.A-C/
p.E143K-Q, m.4171C.A/p.L289M), MT-ND4L (m.10663T.C/p.V65A) and MT-ND6 (m.14459G.A/p.A72V, m.14495A.G/
p.M64I, m.14482C.A/p.L60S, and m.14568C.T/p.G36S). Phylogenetic analyses revealed that these substitutions were due
to independent events on different haplogroups, whereas interspecies comparisons showed that they affected conserved
amino acid residues or domains in the ND subunit genes of complex I.
Conclusions/Significance: Our findings indicate that these nine substitutions are all primary LHON mutations. Therefore,
despite their relative low frequency, they should be routinely tested for in all LHON patients lacking the three common
mutations. Moreover, our sequence analysis confirms the major role of haplogroups J1c and J2b (over 35% in our probands
versus 6% in the general population of Western Europe) and other putative synergistic mtDNA variants in LHON expression.
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Introduction
Leber’s hereditary optic neuropathy (LHON), a blinding
disorder characterized by subacute/acute loss of central vision
that most frequently affects young males, is a maternally inherited
condition associated with mitochondrial DNA (mtDNA) point
mutations [1–3]. It is widely recognized that one of three common
mutations, m.11778G.A, m.3460G.A and m.14484T.C re-
spectively affecting the MT-ND4, MT-ND1 and MT-ND6 subunit
genes of complex I, are present in over 90% of LHON patients. It
is also now established that most of the so-called ‘‘secondary
mutations’’, which may enhance the pathogenic potential and
penetrance of the m.11778G.A and m.14484T.C mutations,
are linked to polymorphic nucleotide changes characterizing
a rather frequent western Eurasian mtDNA haplogroup (hap-
logroup J) and its subclades [4–6].
Neurologists and ophthalmologists commonly encounter pa-
tients with a family history compatible with maternal inheritance,
who fulfill the clinical criteria for LHON but lack the common
mutations upon genetic testing. Complete mtDNA sequencing has
shown in some of these cases the presence of different and rare
nucleotide changes, most of these in the MT-ND6 and MT-ND1
genes, which fit the accepted criteria for being pathogenic and
these genes are now considered mutational hot spots for LHON
[7,8]. Mutations independently found in more than one unrelated
case or family include those in MT-ND6 (m.14482C.G/A,
m.14568C.T, m.14495A.G), and in MT-ND1 (m.4171C.A,
m.3733G.A, and m.3635G.A) [7–21]. An additional mutation,
validated in three families and in strict association with haplogroup
J, is m.10663T.C in MT-ND4L gene [22–24]. A different set of
putative pathogenic mutations has also been reported in single
cases or families; these have been assigned a provisional status and
await confirmation of their strict pathogenic association with
LHON [1,25,26]. They include the variants m.3700G.A/MT-
ND1 [27], m.14498C.T/MT-ND6 [12] and m.4640C.A/MT-
ND2 [18], the latter two are found in mutigenerational pedigrees
with evidence of maternal inheritance. A different class of
mutations, with a higher pathogenic potential leading to LHON
plus MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis
and Stroke-like episodes) or Leigh phenotypes, have also been
described in MT-ND6, MT-ND1, MT-ND3, MT-ND4 and, in
particular, in the MT-ND5 genes of complex I [26]. The prototype
of this category is the mutation m.14459G.A/MT-ND6 [28],
originally found in a large pedigree affected by LHON, spastic
dystonia with bilateral striatal necrosis or a combination of both
[29], but subsequently identified in cases of fatal infantile Leigh
syndrome [30]. Similarly, mutations in the MT-ND5 gene are
typically associated with a wide range of phenotypes, an example
of which is the mutation m.13042G.A that is associated with both
LHON and MELAS in the same maternal lineage, or may lead to
overlapping MELAS/MERRF (Myoclonic Epilepsy, Ragged-Red
Fibers) phenotypes or Leigh syndrome [31–33].
In the present study we analyzed 174 suspected LHON
probands from unrelated families, lacking the three common
mutations, and detected 16 mitochondrial genomes, harboring at
least one rare pathogenic mutation. This study definitively
establishes nine rare mtDNA point mutations as primary LHON
mutations that should be routinely screened for if the three most
common mutations are not identified.
Results
Among the three diagnostic centers involved in this study,
sequencing of a total of 174 complete mitochondrial genomes was
performed in cases highly suspected for LHON, but lacking the
three common mutations (Table S1). Sixteen probands (Text S1)
resulted positive for a rare pathogenic mutation and Figure 1
illustrates the phylogenetic relationships between these mitochon-
drial genomes. As expected the mtDNA sequence from French
family 16, which is originally from Benin, belonged to a sub-
Saharan African haplogroup (L2a1), whereas all other sequences
clustered within a wide range of Western Eurasian haplogroups
within macro-haplogroups N and R. Table 1 summarizes the main
features of each mtDNA sequence. They were all different and
each mtDNA was found to harbor at least one rare LHON
mutation. Because several of the LHON mutations were found in
more than one proband, the overall number of rare LHON
mutations was nine (Tables 1 and 2). In all cases in which the same
mutation was shared by more than one mtDNA, the haplogroup
affiliation and the phylogenetic relationships between mtDNAs
revealed that the sharing is not by descent but due to independent
mutational events (Figure 1). All of them represent non-synony-
mous mutations that cause an amino acidic change in highly
conserved position (.98% within mammals, see Table 2 and
Figure 2), with the only notable exception of m.14482C.A/MT-
ND6 (p.M64I, conservation 58.14%).
Seven of the nine mutations are already listed within the ‘‘Top
10’’ Primary LHON mutations in MITOMAP, while the
m.3700G.A/MT-ND1 transition is reported within the ‘‘other
candidate LHON mutations found as single family or singleton
cases’’. The m.3733G.C/MT-ND1 is not included in either of
these lists. For the sake of clarity, the results for each LHON
mutation are presented separately.
m.3700G.A/MT-ND1 (Families 1 and 2)
The mtDNAs from the probands of family 1 (Italy) (Figure
S1) and the previously reported family 2 (Germany) [27]
harbored the non-synonymous nucleotide change m.3700G.A.
The phylogenetic relationship between the two probands’
sequences show that this mutation is not shared by descent,
but it is due to two independent mutational events (Figure 1):
the first radiates from the root of H, the most common
haplogroup in Europe [34], whereas the second can be further
classified into the H26a subclade [35]. This nucleotide change,
never reported as a population polymorphism, causes the amino
acid substitution p.A132T in the ND1 protein, which has been
previously proposed as pathogenic for LHON in the German
family [27]. The RFLP analysis of the m.3700G.A mutation
showed that it was virtually homoplasmic in DNA from
peripheral blood (data not shown). A DNA sample from
urinary epithelium available only for individual II:1 of family
1 was also homoplasmic mutant. Both cases were apparently
sporadic and no further DNA was available for analyses from
maternal relatives. Thus, following the initial description of
family 2, the pathogenic role of the rare m.3700G.A mutation
is confirmed, with the detection of an Italian LHON patient
(Family 1), as a separate mutational event.
Family 1 harbored also a second non-synonymous change
m.13759G.A/MT-ND5. This nucleotide change is a polymorphic
marker of the Asian haplogroups F1a’c’f and M7c1d [35], and it
has been also sporadically observed in mtDNAs belonging to other
haplogroups.
m.3733G.A-C/MT-ND1 (Families 5, 9 and 14)
The m.3733G.A mutation was detected in two previously
described Italian families (Families 1 and 2 in Valentino et al. [8],
here renamed families 5 and 14, respectively) on haplogroups H10
and X2b, thus indicating that it resulted from two distinct
mutational events (Figure 1). The mutation m.3733G.A causes
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the amino acid substitution p.E143K and in both families was
homoplasmic in the affected individuals, whereas many unaffected
maternal relatives were heteroplasmic [8].
The mtDNA from family 5 revealed the presence of only the
other non-synonymous change m.9091A.G/MT-ATP6, which
has been found in several healthy subjects belonging to
haplogroup H10 [35], thus a role in LHON pathogenicity is very
unlikely.
The mtDNA sequence from family 14 was instead characterized
by numerous non-synonymous changes (see Table 1). As shown in
Figure 1, most of these (m.8393C.T, m.13708G.A and
m.13966A.G) are ancient polymorphisms of haplogroup X2b.
The remaining two substitutions (m.7859G.A and
m.11084A.G) are phylogenetically more recent. The
m.7859G.A nucleotide change was previously reported in
a pediatric case of mitochondrial encephalopathy (patient 2 in
Uusimaa et al. [36]), but no clear pathogenicity was assigned
because it was homoplasmic. Moreover, it has also been found in
different normal individuals associated with at least two different
Asian haplogroups (Y2 and M4) [35]. Similarly, the m.11084A.G
substitution has also been initially reported as pathogenic for
MELAS in an Australian patient [37], but subsequently identified
as a polymorphism of the Asian haplogroups A4e1 and M2a1a1a
[35]. Thus, most probably these changes are polymorphic
variants, but their potential synergistic role is further discussed
based on their conservation pattern.
In the course of this study we also found a family from Germany
(Family 9 in Figure S1) harboring a heteroplasmic (see Figure 3)
variant at the very same position but with a different nucleotide
change, m.3733G.C, leading to a different amino acid sub-
stitution (p.E143Q). Its mtDNA belongs to sub-haplogroup
J1c3e1, a clade characterized by several non-synonymous variants
affecting MT-ND1-6 and MT-CYB genes (Table 1, Figure 1).
Beside those changes established as markers of J1c3e1, we also
note the presence of the change m.14502T.C/MT-ND6. This
variant has been previously reported as the only pathogenic
change in three unrelated sporadic LHON cases from China, in
one Chinese LHON pedigree characterized by complete pene-
trance in combination with the m.14484T.C primary LHON
mutation, and in four additional Chinese unrelated families
Figure 1. Phylogenetic tree of 16 complete mtDNA sequences from LHON patients. Rare LHON mutations are shown in bold. The position
of rCRS [57] is indicated for reading off sequence motifs. Mutations are shown on the branches; they are transitions unless a base is explicitly
indicated. The prefix @ designates reversions, while suffixes indicate: transversions (to A, G, C, or T), indels (+, d), gene locus (,t, tRNA; ,r, rRNA),
synonymous or non-synonymous changes (s or ns) and heteroplasmies (h). Recurrent mutations are underlined. One mtDNA sequence (I; black circle)
from a control subject (GenBank accession number FJ190383) was also included to illustrate that sequences 11 and 12 acquired independently the
LHON mutation m.14568C.T. The haplogroup affiliation of each haplotype is based on mutational motifs and follows the most updated human
phylogeny [35].
doi:10.1371/journal.pone.0042242.g001
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carrying the m.11778G.A mutation [38–40]. The latter two
scenarios parallel the one that we observed in the mtDNA
sequence of family 9, where the m.14502T.C mutation is in
association with the heteroplasmic m.3733G.C mutation. In this
Table 1. List of complete mtDNA sequences included in Figure 1.
Family
ID #a Origin Haplogroupe Non-synonymous nucleotide changesf
GenBank
accession
numberg Reference
1 Italy H 3700, 13759 JN415470 Present study
2 Germany H26a 3700 JN415471 [27]
3 Italy H66 14495 JN415472 Present study
4 Germany H1c1 14568 JN415473 [12]
5 Italy H10 3733, 9091 JN415474 [8]
6 Italy U6a1a1 4172A, 7805, 14568, 14766, 14927, 15221 EF064318.1 Present study
7 Franceb K1a 7299, 9055, 10398, 13759, 14568, 14766, 14798 JN415475 Present study
8 Italy J1c3 4216, 10398, 13708, 13934, 14459, 14766, 14798, 15452A JN415476 Present study
9 Germany J1c3e1 3733C, 4216, 10398, 13145, 13708, 13934, 14502, 14766, 14798, 15452A JN415477 Present study
10 Italy J1c 4216, 10398, 13708, 14482A, 14766, 14798, 15452A JN415478 [11]
11 France J1c2e 4216, 10398, 13708, 14568, 14766, 14798, 15452A JN415479 Present study
12 Germany J1c2 4216, 10398, 13708, 14325, 14568, 14766, 14798, 15452A JN415480 [14]
13 France J2b1 4171A, 4216, 7632, 10398, 13708, 14766, 15257, 15452A, 15812 JN415481 Present study
14 Italy X2b 3733, 7859, 8393, 11084, 13708, 13966, 14766 JN415482 [8]
15 Germanyc I5a 5074, 10398, 13780, 14482A, 14766 JN415483 [10,27]
16 Franced L2a1 8701, 9053, 10398, 10663, 14766 JN415484 Present study
aFamily ID numbers correspond to the numbers in Figure 1.
bThis family is originally from Lebanon.
cThis family is originally from Turkey.
dThis family is originally from Benin.
eHaplogroup classification based on the most updated human mitochondrial phylogeny [35].
fNucleotide positions and changes refer to rCRS [57]. The non-synonymous nucleotide changes at nps 8860 (8860G) and 15326 (15326G), present in all LHON samples,
are not included because they are private mutations of the reference sequence. LHON mutations are in bold, while those with a possible synergistic effect are
underlined.
gOnly the entire mitochondrial sequence #6 was already published (Olivieri et al. [44]).
doi:10.1371/journal.pone.0042242.t001
Table 2. Conservation analysis of rare primary LHON mutations.
Mutation Gene
Heteropl.
Status
Amino Acid
Change
Matches in
GenBanka
Eukaryotes
Cons. (%)
Vertebrates
Cons. (%)
Mammals
Cons. (%)
PolyPhen2
Predict. SIFT Predict. Family
m.3700G.A MT-ND1 – p.A132T 0 79.22 93.52 98.73 Benign Not Tolerated 1, 2
m.3733G.A MT-ND1 2/+ (ref. [8]) p.E143K 1 (FJ944094) 99.35 99.07 98.73 Possibly
Damaging
Not Tolerated 5, 14
m.3733G.C MT-ND1 + (78%) p.E143Q 0 99.35 99.07 98.73 Probably
Damaging
Not Tolerated 9
m.4171C.A MT-ND1 + (80%) p.L289M 0 60.39 84.26 100.00 Probably
Damaging
Tolerated 13
m.10663T.C MT-ND4L – p.V65A 0 79.33 91.73 99.61 Possibly
Damaging
Tolerated 16
m.14459G.A MT-ND6 – p.A72V 1 (AY195748) 54.03 72.29 100.00 Probably
Damaging
Not Tolerated 8
m.14482C.A MT-ND6 2/+ (ref.
[11])
p.M64I 0 64.52 75.90 58.14 Probably
Damaging
Not Tolerated 10, 15
m.14495A.G MT-ND6 + (41%) p.L60S 0 79.03 100.00 100.00 Probably
Damaging
Not Tolerated 3
m.14568C.T MT-ND6 2/+ (60–
90%)
p.G36S 2 (EF064318,
EU545432)
34.68 51.81 100.00 Probably
Damaging
Not Tolerated 4, 6, 7, 11,
12
aThe GenBank database was searched on March 2nd 2012 when a total of 10,304 mtDNA coding regions were deposited.
doi:10.1371/journal.pone.0042242.t002
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context, the m.14502T.C change might worsen the complex I
deficiency caused by the 3733G.C transversion.
m.4171C.A/MT-ND1 (Family 13)
The complete sequencing of mtDNA from the proband of the
small French family 13 (Figure S1), with two maternally related
affected males revealed the heteroplasmic m.4171C.A mutation
(Figure 3), which was previously proposed as pathogenic in two
Korean families [15] and further found in a sporadic case and one
family from China [16,17]. Both Korean mtDNAs harbored
apparently identical sequences belonging to haplogroup A, thus
raising the possibility of a single ancestral mutational event.
However, in one family the proband was apparently a sporadic
case and his mother was heteroplasmic, supporting the alternative
scenario of two independent mutational events. The Chinese cases
were unrelated to the Korean, and one family (haplogroup N9a1)
displayed an almost complete penetrance [17]. In all these cases
further changes affecting MT-ND1-6 and MT-CYB genes were
thought to be putatively synergistic with the m.4171C.A
mutation. The mtDNA of our proband belongs to haplogroup
J2b1 (Figure 1) and this is the first report of the m.4171C.A
mutation associated with LHON on a non-Asian background.
The addition of our case, obviously unrelated, confirms the
pathogenic role of the m.4171C.A mutation and its association
with haplogroup J2b (presenting numerous non-synonymous
polymorphisms) and further suggests the need for synergistic
variants to increase its pathogenicity. Moreover, this mtDNA also
harbored another novel variant, m.7632T.C/MT-COII, whose
synergistic role cannot be excluded (Table 1).
m.10663T.C/MT-ND4L (Family 16)
The complete sequencing of mtDNA from the proband of this
sporadic French case of African descent (Benin) revealed
a haplogroup L2a1 background (Figure 1 and Figure S1) carrying
the m.10663T.C mutation. This mutation was previously
reported in five pedigrees all belonging to different haplogroup J
Figure 2. Sequence alignment and conservation analysis of ND1, ND4L and ND6 protein sequences. Alignments of protein sequences
from eukaryotes and mammals, including Homo sapiens, are reported. The upper lines represent the human sequence with the amino acid changes
induced by the corresponding LHON mutation. Mutated positions are in bold and indicated by an asterisk. Different shading corresponds to
increasing conservation levels: amino acid conservation between 70% and 90% are highlighted in light grey, amino acid conservation between 90%
and 99% are highlighted in dark grey, and invariant positions (100% conservation) are highlighted in black. Alignment gaps are indicated by a hyphen
(-).
doi:10.1371/journal.pone.0042242.g002
Figure 3. RFLP evaluation of heteroplasmy. Electrophoresis on Metaphor gel of the restriction fragments is shown. Wild type and mutant
fragments are indicated with the corresponding size, expressed as base pairs (bps). Non affected negative control individual is indicated as C. DNA
samples were extracted from whole blood, except when indicated: whole blood is indicated as B, urinary epithelium is indicated as U, platelet fraction
is indicated as P, hairs are indicated as H and skeletal muscle is indicated as M. Molecular weight marker is indicated as MWM.
doi:10.1371/journal.pone.0042242.g003
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sub-clades [23,24], thus indicating multiple independent muta-
tional events. Our case is the first in a non-J mtDNA background
and harbored also a combination of non-synonymous polymorph-
isms m.8701A.G/MT-ATP6, m.9053G.A/MT-ATP6 and
m.10398A.G/MT-ND3, for which a synergistic role, similar to
the haplogroup J polymorphisms, may be considered.
m.14459G.A/MT-ND6 (Family 8)
The LHON proband from this Italian family carried a virtually
homoplasmic m.14459G.A mutation (Table 1 and 2, Figure S1).
The pathogenicity of this mutation is well established and
notorious for a variable clinical expression, ranging from LHON,
dystonia or both, and Leigh syndrome [28,30,41,42]. Here, two
maternal relatives of the proband, reported as wheelchair bound
and suffering of ‘‘paralysis’’, were possibly affected with spastic
dystonia. The mtDNA of the family here reported belongs to
haplogroup J1c3, thus reinforcing the previously discussed
synergistic role of this clade.
m.14482C.A/MT-ND6 (Families 10 and 15)
Both families, one Italian and one German of Turkish ancestry,
were previously reported to carry the m.14482C.A mutation
[11,27], but the complete sequence analysis was not available. The
Italian sequence belongs to haplogroup J1c and harbors all the
non-synonymous variants characterizing this haplogroup, whereas
the German family is a member of haplogroup I5a, which is also
characterized by three non-synonymous variants m.5074T.C/
MT-ND2, m.10398A.G/MT-ND3 and m.13780A.G/MT-ND5.
A different nucleotide change affecting the same position
m.14482C.G/MT-ND6 has been previously reported [9] in an
unrelated family of Turkish ancestry, which noticeably belonged to
the haplogroup I. It is conceivable that haplogroup I potentially
plays a role similar to J. Furthermore, a third patient carrying the
m.14482C.A mutation has been reported by screening a large
cohort of patients with optic atrophy from France [43]. In
summary, mutations at position 14482, although affecting a poorly
conserved amino acid (Table 2) that is also changed by the well-
established LHON primary mutation m.14484T.C, must be
considered pathogenic.
m.14495A.G/MT-ND6 (Family 3)
The proband from the Italian family 3 carried the hetero-
plasmic m.14495A.G mutation (see Table 2, Figure 3 and Figure
S1), which represents the third unrelated occurrence of this
mutation in association with LHON [7]. All the cases, including
our (sub-haplogroup H66), belong to haplogroup H and the
mutational events were possibly recent, as suggested by their
heteroplasmic status.
m.14568C.T/MT-ND6 (Families 4, 6, 7, 11 and 12)
This previously reported transition [12–14] was found in five
different mtDNAs, whose phylogenetic analysis indicates in-
dependent mutational events (Figure 1).
In the mtDNA from family 6 (haplogroup U6a1a1, Figure S1)
the m.14568C.T mutation was found heteroplasmic in combi-
nation with five non-synonymous nucleotide changes (see Table 1
and Olivieri et al. [44]). They are all known polymorphic variants,
with the m.4172T.A mutation defining this specific subclade.
This polymorphism induces the p.L289Q change by affecting the
same codon of the previously discussed m.4171C.A pathogenic
mutation. In addition, the m.14568C.T mutation was hetero-
plasmic in multiple tissues from the proband, being approximately
90% in skeletal muscle and urinary sediment, but 60% in blood
leukocyte and platelet fractions. Similar results were obtained by
analyzing multiple tissues from the proband’s brother, whereas all
the remaining maternally related individuals available for analysis
harbored a virtually homoplasmic wild type mtDNA except for the
proband’s mother and maternal aunt who had traces of mutant
mtDNA (Figure 3). The RFLP analysis of the m.4172T.A variant
revealed that it was homoplasmic in all maternal relatives and all
tissues investigated (data not shown).
The same pathogenic mutation m.14568C.T was also found in
two unrelated French families, which belonged to haplogroups
K1a (family 7) and J1c2e (family 11), respectively. In both cases the
mutation was homoplasmic in the probands. Besides the
haplogroup J-related non-synonymous changes of mtDNA from
family 11, the mtDNA from family 7 harbored a collection of non-
synonymous variants (Table 1).
Finally, we also re-examined by complete mtDNA sequencing
the two originally reported German cases carrying the
m.14568C.T mutation (families 4 and 12) [12,14]. The proband
from family 4 belonged to haplogroup H1c1 with no further non-
synonymous changes besides the pathogenic mutation, whereas
the proband from family 12 clustered within haplogroup J1c2, thus
harbored all non-synonymous changes characterizing this hap-
logroup [35]. Overall, two of the five families carrying the
m.14568C.T mutation were associated with haplogroup J1c, and
one further family had the interesting association with a variant
affecting the same amino acid changed by the LHON pathogenic
m.4171C.A mutation, again emphasizing the importance of the
mtDNA background sequence variation.
Interspecies Conservation Analysis of Pathogenic
Mutations and Non-synonymous Variants
The mutation m.3700G.A/MT-ND1 causes the substitution of
the non-polar p.A132 with a polar T and affects a highly
conserved position (Table 2). Similarly, the mutations
m.3733G.A/MT-ND1 and m.3733G.C/MT-ND1 induce the
amino acid substitutions p.E143K or p.E143Q, respectively. The
position affected is extremely conserved (Table 2) and both
mutations cause a change in the chemical properties from the
acidic glutamic acid, which is negatively charged, to either the
positively charged, basic lysine or the uncharged, polar glutamine.
Remarkably, these three mutations (m.3700G.A, m.3733G.A
and m.3733G.C) affect the same highly conserved region of the
ND1 protein (Figure 2), suggesting an important role of this
conserved domain in complex I function or structure. The
mutation m.4171C.A/MT-ND1 also affects the highly conserved
position p.L289 (Table 2), which is invariant in mammals, and
leads to the substitution with methionine. Interestingly, the
polymorphism m.4172T.A/MT-ND1, found in family 6 mtDNA
and considered a polymorphic marker of haplogroup U6a2, affects
the same p.L289, causing the replacement of the non-polar leucine
with the negatively charged glutamic acid, suggesting a probable
synergistic role of this polymorphism in LHON pathogenesis co-
occurring with the primary mutation m.14568C.T/MT-ND6.
The m.10663T.C/MT-ND4L mutation induces the conserva-
tive amino acid substitution valine to alanine at position 65; the
residue is moderately conserved along eukaryotes but becomes
highly conserved in vertebrates and mammals (Table 2).
Four of the five mutations in the MT-ND6 gene are
concentrated in a hyper-conserved region of the protein and
mostly affect highly conserved positions. The m.14459G.A/MT-
ND6 mutation causes a conservative p.A72V replacement. The
p.A72 is highly conserved along vertebrates and becomes invariant
in mammals, underlying a major functional role of this amino acid
in the ND6 subunit. Similar features characterize the amino acid
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substitution generated by the mutation m.14495A.G/MT-ND6.
This mutation causes the replacement of the highly conserved
non-polar p.L60, which is invariant in vertebrates and mammals
(Table 2), with a polar serine. Within this highly conserved amino
acid stretch of ND6, a remarkable exception is the residue p.M64,
affected by the mutations m.14482C.A-G. In fact, this mutation
induces a conservative change (p.M64I) and hits a position with
a low degree of conservation (see Table 2 and Figure 2) which is,
however, contiguous to invariant stretches of amino acid positions
characterizing this highly conserved domain of the MT-ND6 gene
in mammals (Figure 2). Finally, the m.14568C.T/MT-ND6
mutation affects the amino acid residue p.G36 that is moderately
conserved along eukaryotes and vertebrates, but becomes in-
variant in mammals, again suggesting the acquisition of a partic-
ular role of this position during evolution. Two different predictive
tools (PolyPhen2 and SIFT) were also used to evaluate the
pathogenic potential of the nine novel rare mtDNA variants. All
mutations were classified as ‘‘possibly/probably damaging’’ or
‘‘not tolerated’’ by at least one software, and for 67% of these (six
out of nine, Table 2), both algorithms highlighted the possible
pathogenic effect.
Considering the 28 non-synonymous polymorphic variants
identified in the 16 completely sequenced mtDNAs (see Figure 1),
14 were over the threshold of 70% conservation in mammals
(Table S2). As already noted, the m.4172T.A/MT-ND1 poly-
morphism, a marker of haplogroup U6a2, stands out by affecting
the same invariant p.L289 (100% conservation) as the LHON
primary mutation m.4171C.A/MT-ND1. A further group of
polymorphisms with very high degree of conservation in
mammals (90%–100%) included five variants: m.7632T.C is
a private mutation of a J2b1 sample; m.13145G.A and
m.15257G.A are markers of J subclades; the remaining two
(m.9055G.A and m.14927A.G) define two different U
branches (U8b and U6a1, respectively). Other seven polymorph-
isms had a conservation pattern between 70% and 90%. Finally,
we also applied the two in-silico predictors (PolyPhen2 and SIFT)
to further assess the functional impact of these polymorphic
changes on mtDNA encoded proteins. Nine amino acid
substitutions were independently predicted as damaging or not
tolerated by these tools (Table S2). As expected, the poly-
morphism m.4172T.A/MT-ND1 is the only one that is
predicted to have a functional impact by both algorithms,
because it hits the same p.Leu298 amino acid of the LHON
primary mutation m.4171C.A/MT-ND1, which is invariant in
mammals.
To further characterize the possible functional role of the non-
conserved polymorphic variants, we extended the conservation
analysis on the protein region surrounding these polymorphisms.
Eight out of 15 had an invariant amino acid within four
contiguous amino acidic positions (+4/24 aa, Table S3) and four
of these hit a protein region with a local conservation higher or
equal to the global conservation of the protein subunit, suggesting
that the protein regions containing these variants may represent
functional domains. Remarkably, two ancient variants defining
haplogroups J (m.13708G.A) and X (m.13708G.A and
m.8393C.T) were selected by both analyses, supporting their
possible functional role. In particular, the m.13708G.A/MT-
ND5 variant has been repeatedly associated with LHON as
a secondary mutation.
Discussion
Sequencing of the mitochondrial genomes from 16 sporadic or
familial LHON cases, selected by using stringent clinical criteria
and the strict maternal segregation of the phenotype, revealed nine
rare point mutations with a number of features routinely employed
to validate a pathogenic mtDNA mutation: (i) they arose multiple
times on different mtDNA backgrounds (Figure 1); (ii) they affect
conserved amino acid positions (Figure 2); (iii) they are virtually
absent from population surveys and public datasets (see Table 2);
(iv) they are strictly associated with LHON; (v) they are, in some
instances, heteroplasmic along the maternal line indicating a recent
de novo event (Figure 3). Overall, the rare mutations
m.14568C.T/MT-ND6 (6 cases), m.10663T.C/MT-ND4L (6
cases), and m.4171C.A/MT-ND1 (5 cases) were found more
frequently, whereas others were found less frequently such as
m.14482C.A-G/MT-ND6 (4 cases), m.14495A.G/MT-ND6 (3
cases), m.3733G.A-C/MT-ND1 (3 cases) and m.3700G.A/MT-
ND1 (2 cases). Concerning the m.14459G.A mutation, this has
been clearly established as pathogenic in multiple pedigrees
expressing a phenotype of variable severity, ranging from LHON
to spastic dystonia or Leigh syndrome. Thus, we may consider this
mutation as belonging to a different category of LHON ‘‘plus’’
mutations.
Multiple occurrences on different mtDNAs haplogroup of
putative primary LHON mutations are crucial to assign a patho-
genic role. In most cases the mutations listed above were
homoplasmic along multiple generations of single maternal
lineages. However, in a few families, we have been able to
document mutations in heteroplasmic state in close maternal
relatives of the probands (Figure 3), thus showing a recent
occurrence of the mutational event, which has been frequently
suggested as additional evidence of pathogenicity. In two families,
we observed the co-occurrence of two nucleotide changes with the
primary mutation and in both cases they may play a relevant role
for the pathogenic expression of LHON. In one case, family 9, one
mutation (the heteroplasmic change m.3733G.C) could be
considered pathogenic, while the other (m.14502T.C) could
modulate its penetrance. In a few other cases previously reported,
the co-occurrence of two pathogenic mutations was noted, and in
most instances one of these was heteroplasmic [45–47].
Important criteria used to validate a pathogenic mutation are
the degree of interspecies conservation of the affected amino acid
position and the physical/chemical characteristics of the amino
acid change. All primary mutations affected highly conserved or
invariant amino acid positions or less conserved amino acid
positions within highly conserved protein domains, in particular
when restricting the analyses to mammals. Most primary
mutations induced non-conservative amino acid changes, fre-
quently introducing drastic modifications in the specific residue.
Concerning the ND1 subunit, all confirmed LHON mutations
affect highly conserved extra-membrane loops, whereas most of
the confirmed LHON mutations in ND6 affect the third trans-
membrane helix, the most conserved in ND6 protein. These
findings firmly establish that both MT-ND6 and MT-ND1 genes
are hot spots for LHON mutations, as previously suggested [7,8].
The functional relevance of these mutations is not assessed in the
present study, and formal demonstration of the biochemical
consequences is under way by transferring the mutant mtDNAs to
cybrid cell lines [48]. However, considering the recent break-
through in understanding complex I function due to its crystal
structure elucidation [49,50], we may anticipate that MT-ND1
mutations will affect more consistently the electron transfer to the
quinone substrate and complex I redox activity, whereas MT-ND6
mutations may be more relevant for the ‘‘piston-driven’’ proton
translocation and the energy conserving function [51–53].
The complete sequence data for the 16 mtDNAs here
investigated also highlight the role played by certain hap-
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logroup-specific non-synonymous variants, as well as the
frequent co-occurrence of private sets of putative synergistic
non-synonymous changes or double mutants (Table 1), all
potentially relevant in modulating penetrance and severity of the
primary LHON mutations. The high occurrence of haplogroups
J1c and J2b (over 35%) in our limited set of patients is 5.6 fold
that observed in the general population of Western Europe
(6.2% in total; 5.3% in France, 6.6% in Germany and 6.2% in
Italy) [54]. This finding further supports the role of these two
mtDNA backgrounds in increasing LHON penetrance. A
similar effect may be played also by haplogroup I, as suggested
by the association with the m.14482C.A-G mutation [9,27].
An apparent paradox is represented by the m.4171C.A
LHON primary mutation and the m4172T.A polymorphic
variant, both affecting the same amino acid position in ND1,
but inducing different amino acid changes, p.L289M and
p.L289Q respectively. The less conservative p.L289Q change is
apparently tolerated as a polymorphism in the haplogroup U6a
[35], whereas the p.L289M has been established as an LHON
primary rare mutation [15–17 and present study]. Thus, the
mtDNA background is remarkably important in determining the
role of amino acid changes affecting the same position in
a different mtDNA context. Such a borderline situation applies
also to the m.14484T.C and m.14482C.A-G mutations in
MT-ND6. In fact, they affect one of the less conserved amino
acid positions among LHON primary mutations and represent,
by far, the best example of the need for a tight association with
specific haplogroups (J and I) to express their pathogenic
potential. Compatibly, the m.14484T.C mutation has been
identified in a few instances as a non-synonymous variant in
population surveys, apparently without expressing any patho-
logical phenotype (Antonio Torroni, unpublished observation
and ref. [35]). Furthermore, it must be recalled that this
mutation was judged as a non-pathogenic variant when it was
first observed in LHON pedigrees [55]. Thus, we may predict
that the m.4172T.A change behaves as a polymorphic variant
in the context of haplogroup U6a, and may exert a pathogenic
role if found in a different mtDNA background. Remarkably,
both affected individuals in family 6 of the present study were
heteroplasmic with variable mutant loads of the heteroplasmic
m.14568C.T primary mutation co-occurring with the homo-
plasmic m.4172T.A change, suggesting a possible synergistic
role for the latter. The blurry scenario revealed by these
findings complicates the set of rules necessary to clearly assign
a pathogenic role to a non-synonymous homoplasmic change in
mtDNA and emphasizes the importance of sequencing the
entire mtDNA in every LHON case. The assignment of
a pathogenic role for an mtDNA variant remains a complex
issue, as recently documented for the m.3394T.C mutation,
which may behave as a weak pathogenic mutation for LHON
or an adaptative polymorphic variant depending on the mtDNA
background [56].
Based on this study we propose a revised diagnostic flow chart
for LHON, which may include the following steps: (a) standard
screening for the three common primary mutations; (b) if negative,
sequence analysis the MT-ND6 and MT-ND1 genes; (c) if negative,
complete mtDNA sequencing. The latter may be an option, when
possible, to exhaustively study any case of LHON.
In conclusion, the nine mutations validated here should now be
included as confirmed primary LHON mutations in public
databases such as MITOMAP. These mutations are rare, but
occurred multiple times in maternal lineages, and probably
account for an important fraction of the about 10% of LHON
patients who are negative for the three common mutations.
Methods
Ethics Statement
All experimental procedures and written informed consent,
obtained from all donors, were reviewed and approved by the
following Ethics Committee: Comitato etico indipendente dell’A-
zienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-
Malpighi, Prot. n. 789/2007.
Mitochondrial DNA Complete Sequencing and
Phylogenetic Analyses
DNAs were extracted from venous blood. Sequencing of entire
mtDNAs and phylogeny construction was performed as previously
described [34]. All the mutations are relative to the revised
Cambridge Reference Sequence (rCRS) [57]. The complete
mtDNA sequences of the 16 case reports have been deposited in
GenBank (Table 1).
Evaluation of Heteroplasmy for Rare LHON Mutations
Heteroplasmy/homoplasmy status of the rare LHON mutations
was evaluated by RFLP analysis of PCR amplified mtDNA
fragments encompassing the position of the mutant nucleotide.
The list of the primers and restriction enzymes used for each
mutation are listed in Table S4. Fragments were separated by
electrophoresis on Metaphor (BioSpa) gel at 3% or 4% and
detected by ethidium bromide staining. Quantification of muta-
tional load was carried out by densitometric analysis using
AlphaView software package (Cell Biosciences).
Alignment of Protein Sequences and Interspecies
Conservation Analysis
The interspecies conservation of the amino acidic positions
changed by pathogenic mutations and non-synonymous poly-
morphic variants, detected in our mtDNA complete sequences,
was calculated and, as a general rule, all the polymorphisms above
a conservation threshold (70%) were considered ‘‘possibly
synergistic’’.
All the available complete mitochondrial protein sequences
were downloaded from the non-redundant SwissProt database
(http://www.expasy.org/sprot) and three sequence sets were
created, corresponding to eukaryotes, vertebrates and mammals.
These sequences were aligned as previously reported [58], the
most representative amino acidic residues were identified and their
prevalence was calculated at each position within the alignment,
setting the value of 70% as conservation threshold.
To assess the possible functional effect of primary rare
mutations and non-synonymous polymorphic variants four differ-
ent prediction tools available on line were applied: PolyPhen2,
SIFT, SNP&GO and PROVEAN 1.0 [59–62]. The accuracy of
these tools was tested on the confirmed pathogenic mtDNA
mutations in MT-ND1-6 genes listed in MITOMAP [26].
Eventually, we adopted PolyPhen2 and SIFT that resulted the
most accurate algorithms predicting as damaging or not tolerated
15/16 of the tested mutations.
The non-synonymous polymorphic variants were clustered in
ancient or recent changes, depending on their position along the
phylogenetic tree, and the percentage of conserved and non-
conserved amino acid positions was calculated within each cluster.
Further analyses of the non-conserved amino acid changes
induced by non-synonymous polymorphic variants included the
estimate of the local conservation and number of conserved amino
acids around the affected position (210/+10 amino acids), which
was compared to the global conservation and the total number of
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conserved amino acids of the entire protein. Those polymorphisms
inducing amino acidic changes at positions with both parameters
higher than the global conservation and number of conserved
amino acid were considered ‘‘possibly synergistic’’. Finally, the
closest invariant (100% conservation) position for each amino acid
change was identified and the polymorphic changes hitting amino
acidic positions nearby invariant positions (24/+4 amino acids)
were considered ‘‘possibly synergistic’’.
Supporting Information
Figure S1 Pedigrees of LHON families. Family ID numbers,
mtDNA mutations and haplogroup affiliations are reported.
Symbol definitions are also indicated. Probands are identified by
black arrows.
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